$863.72 Million in Sales Expected for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) This Quarter

Brokerages predict that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will announce $863.72 million in sales for the current quarter, according to Zacks. Seven analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $877.05 million and the lowest estimate coming in at $852.75 million. Jazz Pharmaceuticals reported sales of $665.52 million in the same quarter last year, which indicates a positive year-over-year growth rate of 29.8%. The business is expected to announce its next quarterly earnings results on Tuesday, February 22nd.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year sales of $3.06 billion for the current fiscal year, with estimates ranging from $3.05 billion to $3.07 billion. For the next fiscal year, analysts expect that the company will post sales of $3.63 billion, with estimates ranging from $3.53 billion to $3.80 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 9th. The specialty pharmaceutical company reported $4.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.60 by $1.60. Jazz Pharmaceuticals had a positive return on equity of 21.43% and a negative net margin of 5.62%. The business had revenue of $838.12 million for the quarter, compared to the consensus estimate of $829.98 million. During the same quarter last year, the business posted $3.86 EPS.

A number of analysts recently issued reports on JAZZ shares. Citigroup assumed coverage on Jazz Pharmaceuticals in a research note on Tuesday, October 5th. They set a “buy” rating and a $200.00 target price for the company. Needham & Company LLC assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 22nd. They set a “buy” rating and a $220.00 price objective for the company. Morgan Stanley cut their price objective on shares of Jazz Pharmaceuticals from $176.00 to $174.00 and set an “equal weight” rating on the stock in a research report on Friday, October 8th. The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, November 18th. They issued a “buy” rating for the company. Finally, HC Wainwright dropped their price target on Jazz Pharmaceuticals from $220.00 to $210.00 and set a “buy” rating on the stock in a research note on Monday, August 16th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $210.36.

In other news, SVP Finbar Larkin sold 197 shares of the business’s stock in a transaction dated Friday, November 12th. The shares were sold at an average price of $135.79, for a total value of $26,750.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 6,556 shares of the business’s stock in a transaction dated Monday, November 1st. The shares were sold at an average price of $134.75, for a total transaction of $883,421.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,162 shares of company stock worth $2,146,536. Insiders own 4.30% of the company’s stock.

Several large investors have recently modified their holdings of JAZZ. Oppenheimer Asset Management Inc. increased its stake in Jazz Pharmaceuticals by 1.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,665 shares of the specialty pharmaceutical company’s stock valued at $1,006,000 after acquiring an additional 65 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 3.8% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,000 shares of the specialty pharmaceutical company’s stock valued at $330,000 after purchasing an additional 73 shares in the last quarter. Confluence Investment Management LLC increased its stake in shares of Jazz Pharmaceuticals by 2.7% in the 3rd quarter. Confluence Investment Management LLC now owns 3,178 shares of the specialty pharmaceutical company’s stock valued at $414,000 after purchasing an additional 84 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 3.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 3,106 shares of the specialty pharmaceutical company’s stock worth $404,000 after buying an additional 90 shares in the last quarter. Finally, Kestra Advisory Services LLC lifted its position in shares of Jazz Pharmaceuticals by 3.1% during the 3rd quarter. Kestra Advisory Services LLC now owns 3,095 shares of the specialty pharmaceutical company’s stock worth $403,000 after buying an additional 93 shares during the last quarter. Institutional investors own 91.42% of the company’s stock.

Shares of NASDAQ JAZZ traded down $0.24 during mid-day trading on Friday, reaching $129.31. 288,927 shares of the company’s stock were exchanged, compared to its average volume of 681,663. Jazz Pharmaceuticals has a twelve month low of $126.01 and a twelve month high of $189.00. The company has a current ratio of 3.58, a quick ratio of 2.03 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -50.71, a PEG ratio of 0.69 and a beta of 0.91. The business has a fifty day simple moving average of $134.84 and a 200 day simple moving average of $154.25.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Read More: Example of operating income, EBIT and EBITDA

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.